Montelukast API - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The montelukast API market size is projected to be USD 4.73 billion in 2025, USD 5.29 billion in 2026, and reach USD 9.21 billion by 2031, growing at a CAGR of 11.75% from 2026 to 2031. This report is segmented by Product Type (Amorphous, Crystalline), Dosage-Form Compatibility (Film-Coated Tablets, Chewable Tablets, Oral Granules, Oral Solutions/Syrups), Application (Asthma, Allergic Rhinitis, Exercise-Induced Bronchoconstriction, Urticaria, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Montelukast API Market Trends and Insights

Rising Asthma and Allergic Rhinitis Treatment Demand

The Montelukast API market draws its core volume from respiratory and allergy treatment needs that persist across healthcare systems, even when local prescribing practices differ. The World Health Organization reported that asthma affected 363 million people in 2025. This patient base supports ongoing demand for an oral leukotriene receptor antagonist in generic medicine portfolios, where treatment decisions also reflect affordability and local access to specialist care. Allergic rhinitis can occur alongside asthma, which can add to treatment demand rather than simply shift use between indications. The Montelukast API market benefits where diagnosis, patient awareness, and primary care access improve in lower-income settings, because these changes can convert previously untreated respiratory symptoms into regular medicine use. The resulting demand is most durable when suppliers can support both established asthma treatment and allergy-related formulations with consistent quality, dependable documentation, and commercially practical order sizes.

Generic-First Payer Economics

Generic substitution and step-therapy practices support recurring procurement of montelukast in North America and Europe, where payers often look for affordable treatment options before approving more complex therapies. These practices can keep a low-cost oral treatment in formularies before a patient moves to more costly therapies, which gives procurement planning a degree of continuity. The Montelukast API market therefore retains a base of repeat purchasing even when prescribers weigh competing clinical options and guideline recommendations. Lower finished-dose prices can limit revenue per unit, but they can also support broad access, recurring prescription use, and sustained order volumes for established products. Producers with suitable regulatory documentation can be favored in longer supply arrangements for regulated destinations, because changing an API source can create a significant qualification burden for the finished-dose customer. This pattern makes reliability, quality records, market-specific filings, and the ability to respond to audits as important as price in supplier decisions.

Safety, Pricing, and Compliance Pressures

The FDA requires a Boxed Warning for montelukast because of serious mental health side effects, including suicidal thoughts and actions. For allergic rhinitis, the FDA advises reserving the medicine for patients who have not responded to, or cannot tolerate, other allergy medicines. A Swedish cohort study published in 2025 covering 74,291 children and adolescents found no statistically significant difference in neuropsychiatric adverse events between montelukast and LABA users, with a hazard ratio of 0.99 and a 95.00% confidence interval of 0.84 to 1.16. The warning can reduce new starts for allergic rhinitis while having less effect on established asthma treatment, creating a different impact across application areas. Mature generic competition continues to pressure prices across the Montelukast API market, particularly when multiple qualified sources can bid for the same tablet program. At the same time, nitrosamine assessments, testing, and synthetic-route documentation can raise qualification costs and limit the suppliers able to serve regulated channels, making compliance expense a practical restraint for smaller producers.

Other drivers and restraints analyzed in the detailed report include:

• Pediatric Chewable and Granule Demand
• Extended Allergy Seasons and Perennial Rhinitis
• Shift Toward Inhaled Corticosteroid-Based Treatment Pathways

Segment Analysis

Montelukast Sodium Crystalline held 64.70% of the Montelukast API market share by product type in 2025. Its position reflects extensive manufacturing validation and established quality agreements with film-coated tablet producers. The form offers physical stability and predictable compressibility during high-volume tableting. These attributes can reduce process variability for generic finished-dose manufacturers. Storage and handling practices are also familiar to many existing formulation facilities. The crystalline form, therefore, remains closely linked to adult and adolescent tablet demand.

Montelukast Sodium Amorphous is forecast to grow at an 11.40% CAGR from 2026 to 2031. Its higher apparent solubility and faster dissolution support oral granules and oral solution matrices. This makes the form relevant to products intended for younger patients. Shilpa Pharma Lifesciences received a Certificate of Suitability CEP 2024-125 for montelukast sodium in amorphous form. Stability expectations for amorphous materials place a greater emphasis on documentation and technical controls. These requirements can favor suppliers with the capacity to maintain robust quality packages.

Complete Report Scope:

• By Product Type
  • Montelukast Sodium Amorphous
  • Montelukast Sodium Crystalline
• By Dosage-Form Compatibility
  • Film-Coated Tablets
  • Chewable Tablets
  • Oral Granules
  • Oral Solutions, Suspensions, and Syrups
• By Application
  • Asthma
  • Allergic Rhinitis
  • Exercise-Induced Bronchoconstriction
  • Urticaria
  • Other Respiratory and Allergic Applications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.50% of the Montelukast API market share in 2025. The region has a developed generic formulation system and extensive managed-care use of step-therapy protocols. These conditions support predictable procurement for qualified API suppliers. The FDA Boxed Warning introduces limits on allergic rhinitis initiation, but established asthma use remains important. Longer pollen seasons can support allergy-related prescribing over a greater part of the year. Health Canada updated its nitrosamine guidance in August 2025, adding compliance considerations for suppliers to Canadian import channels.

Europe remains a technically demanding destination for the Montelukast API market. The European Medicines Agency and CMDh published joint guidance on nitrosamine impurity risk management in July 2025. The guidance includes nitrosamine drug substance-related impurities and strengthens the focus on mitigation and control. Suppliers serving the region need clear quality and regulatory documentation. Earlier and extended seasons for specific pollen types in Central European cities support a wider allergic rhinitis treatment period. Safety advice in the United Kingdom can temper prescribing while not removing the oral treatment option.

Asia-Pacific is forecast to expand at a 14.50% CAGR between 2026 and 2031, the highest regional rate in the Montelukast API market. India is an important source of API supply for regulated export markets. Regional demand also comes from China, India, Japan, South Korea, and Australia. Pediatric formats and allergy treatment needs provide a route for broader use across the region. South America and Middle East and Africa begin from smaller procurement bases. Brazil uses ANVISA-regulated pathways, while Gulf Cooperation Council tenders can increase the emphasis on qualified API supply. The geographic mix rewards suppliers able to meet different regulatory and formulation requirements without weakening quality controls.

List of Companies Covered in this Report:

• Aarti Pharmalabs Limited
• Aurobindo Pharma
• Cipla
• Dr. Reddy’s Laboratories
• Glenmark Pharmaceuticals
• Hetero Labs Limited
• Hikma Pharmaceuticals
• Intas Pharmaceutical
• Lupin
• Merck
• Metrochem API Private Limited
• Morepen Laboratories Limited
• MSN Laboratories Private Limited
• Sandoz Group AG
• Shilpa Pharma Lifesciences Limited
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals Limited
• Unichem Laboratories Limited
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support